Peter A Van Dam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6790522/publications.pdf

Version: 2024-02-01

96	5,133	117625	91884
papers	citations	34 h-index	69 g-index

98	98	98	7007
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	1.6	582
2	Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer, 2003, 103, 642-646.	5.1	365
3	Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival. Clinical Cancer Research, 2004, 10, 7157-7162.	7.0	309
4	The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology, 2020, 60, 41-56.	9.6	226
5	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	7.0	215
6	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011, 17, 3600-3618.	7.0	207
7	The role of Nuclear Factor-kappa B signaling in human cervical cancer. Critical Reviews in Oncology/Hematology, 2017, 120, 141-150.	4.4	200
8	FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology, 2017, 113, 256-267.	4.4	167
9	Tumor Lymphangiogenesis in Inflammatory Breast Carcinoma: A Histomorphometric Study. Clinical Cancer Research, 2005, 11, 7637-7642.	7.0	152
10	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	7.0	130
11	Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?. American Journal of Obstetrics and Gynecology, 1999, 181, 536-541.	1.3	128
12	Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility, 2008, 90, 17-22.	1.0	112
13	Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Research and Treatment, 2006, 95, 243-255.	2.5	105
14	Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis. Breast Cancer Research and Treatment, 2005, 93, 237-246.	2.5	104
15	Nuclear Factor-ÎºB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-ÎºB DNA-Binding. Clinical Cancer Research, 2006, 12, 3249-3256.	7.0	101
16	Increased Sentinel Lymph Node Lymphangiogenesis is Associated with Nonsentinel Axillary Lymph Node Involvement in Breast Cancer Patients with a Positive Sentinel Node. Clinical Cancer Research, 2007, 13, 5391-5397.	7.0	91
17	The interaction between ER and NFÎºB in resistance to endocrine therapy. Breast Cancer Research, 2012, 14, 212.	5.0	89
18	Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Research and Treatment, 2006, 95, 219-228.	2.5	87

#	Article	IF	Citations
19	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open, 2018, 3, e000398.	4.5	79
20	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	7.0	76
21	Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination. PLoS ONE, 2010, 5, e12616.	2.5	74
22	Decreased expression of ABAT and STC2 hallmarks ERâ€positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, 2015, 9, 1218-1233.	4.6	64
23	SARS-CoV-2 and cancer: Are they really partners in crime?. Cancer Treatment Reviews, 2020, 89, 102068.	7.7	60
24	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2019, 133, 85-91.	4.4	57
25	Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Research and Treatment, 1997, 42, 165-172.	2.5	50
26	Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology, 1998, 178, 113-117.	1.3	49
27	Genomic profiling of inflammatory breast cancer: A review. Breast, 2014, 23, 538-545.	2.2	46
28	Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. Gynecologic Oncology, 1991, 42, 256-264.	1.4	43
29	Epithelioid Sarcoma of the Vulva. Gynecologic Oncology, 1999, 73, 160-164.	1.4	40
30	Carcinoma in episiotomy scars. Gynecologic Oncology, 1992, 44, 96-100.	1.4	39
31	The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE, 2020, 15, e0231058.	2.5	39
32	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	3.7	38
33	Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: A prospective randomized trial. American Journal of Obstetrics and Gynecology, 1996, 174, 943-950.	1.3	37
34	Sentinel node detection in patients with vaginal carcinoma. Gynecologic Oncology, 2004, 92, 89-92.	1.4	37
35	Inflammatory breast cancer: current understanding. Current Opinion in Oncology, 2006, 18, 563-571.	2.4	36
36	Tripleâ€negative breast cancerâ€”Role of immunology: A systemic review. Breast Journal, 2020, 26, 995-999.	1.0	36

#	Article	IF	Citations
37	The use of rectus abdominis myocutaneous flaps following excision of vulvar cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 1990, 97, 1020-1025.	2.3	35
38	Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Nodeâ€“Negative Breast Cancer. Clinical Cancer Research, 2008, 14, 2944-2952.	7.0	35
39	Interval debulking surgery: An alternative for primary surgical debulking?. Journal of Surgical Oncology, 2000, 19, 49-53.	1.4	33
40	Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer. Clinical Cancer Research, 2008, 14, 7452-7460.	7.0	28
41	Application of ultrasound in the diagnosis of heterotopic pregnancyâ€”a review of the literature. Journal of Clinical Ultrasound, 1988, 16, 159-165.	0.8	27
42	Study of numerical aberrations of chromosome 1 by fluorescent in situ hybridization and DNA content by densitometric analysis on (pre)-malignant cervical lesions. The Histochemical Journal, 1995, 27, 24-34.	0.6	27
43	Prognostic Significance of Disseminated Tumor Cells as Detected by Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction in Patients with Breast Cancer. Clinical Breast Cancer, 2006, 7, 146-152.	2.4	27
44	A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002â€“2010. World Journal of Surgical Oncology, 2013, 11, 70.	1.9	27
45	Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer. European Journal of Cancer, 2022, 163, 177-179.	2.8	26
46	Retroperitoneal Soft Tissue Sarcomas. Obstetrical and Gynecological Survey, 1990, 45, 670-682.	0.4	25
47	Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma. PLoS ONE, 2011, 6, e22469.	2.5	24
48	Sentinel Node Metastasis in the Groin Detected by Technetium-Labeled Nannocolloid in a Patient with Cervical Cancer. Gynecologic Oncology, 2002, 86, 358-360.	1.4	23
49	Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?. Current Opinion in Oncology, 2005, 17, 551-558.	2.4	23
50	Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clinical and Experimental Metastasis, 2007, 24, 13-23.	3.3	23
51	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Research and Treatment, 2014, 147, 557-570.	2.5	23
52	A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial. Breast, 2020, 53, 23-32.	2.2	23
53	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. International Journal of Molecular Sciences, 2019, 20, 2183.	4.1	22
54	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	4.6	22

#	Article	IF	Citations
55	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. , 2022, 236, 108107.		22
56	Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. American Journal of Obstetrics and Gynecology, 1999, 181, 554-559.	1.3	21
57	In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget, 2016, 7, 2780-2795.	1.8	20
58	Fulvestrant (Faslodexâ„¢) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Research and Treatment, 2008, 109, 59-65.	2.5	19
59	Potential new biomarkers for squamous carcinoma of the uterine cervix. ESMO Open, 2018, 3, e000352.	4.5	18
60	Inflammatory breast cancer cells are characterized by abrogated TGFÎ²1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment, 2020, 180, 385-395.	2.5	18
61	Primary Extrauterine MÃ¼llerian Adenosarcoma of the Peritoneum. Gynecologic Oncology, 1995, 57, 126-130.	1.4	15
62	The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opinion on Investigational Drugs, 2009, 18, 1885-1891.	4.1	15
63	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Breast, 2014, 23, 453-459.	2.2	15
64	The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Cancer Treatment and Research Communications, 2019, 19, 100123.	1.7	15
65	Quality indicators for the management of endometrial, cervical and ovarian cancer. European Journal of Surgical Oncology, 2019, 45, 528-537.	1.0	15
66	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. Supportive Care in Cancer, 2021, 29, 859-867.	2.2	14
67	Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 2021, 148, 328-339.	2.8	14
68	A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples. PLoS ONE, 2014, 9, e89262.	2.5	13
69	Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2. Cancer, 1991, 68, 169-177.	4.1	12
70	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	3.7	12
71	Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform. ESMO Open, 2020, 5, e000817.	4.5	11
72	The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers, 2021, 13, 4656.	3.7	10

#	Article	IF	Citations
73	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. Cancers, 2021, 13, 5718.	3.7	10
74	Prostacyclin/Thromboxane Ratio in Human Breast Cancer. Tumor Biology, 1991, 12, 261-266.	1.8	8
75	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. International Journal of Molecular Sciences, 2021, 22, 1807.	4.1	8
76	Bone metastases in the era of targeted treatments: insights from molecular biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 98-111.	0.7	8
77	High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!. European Journal of Cancer, 2020, 138, 225-227.	2.8	7
78	HIPEC in advanced epithelial ovarian cancer: why is there controversy?. Current Opinion in Oncology, 2020, 32, 451-458.	2.4	6
79	Flow cytometric quantitation of tumor-associated antigens in solid tumors. American Journal of Obstetrics and Gynecology, 1990, 163, 698-699.	1.3	5
80	Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: Do they have any significance?. Maturitas, 2006, 55, 94-95.	2.4	5
81	Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer. Obstetrics and Gynecology, 2006, 107, 207-208.	2.4	5
82	Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix. European Journal of Surgical Oncology, 2017, 43, 2245-2247.	1.0	5
83	The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic. British Journal of Cancer, 2021, 124, 1366-1372.	6.4	5
84	The immunologic aspects in hormone receptor positive breast cancer. Cancer Treatment and Research Communications, 2020, 25, 100207.	1.7	4
85	Oncological outcome, postoperative complications, and mammographic changes after intraoperative radiotherapy with electrons (IOERT) as a boost in a large singleâ€institution cohort of breast cancer patients. Breast Journal, 2020, 26, 1937-1945.	1.0	4
86	Meeting the Challenges in Cancer Care Management During the SARS-Cov-2 Pandemic: A Retrospective Analysis. Cancer Control, 2021, 28, 107327482110452.	1.8	4
87	The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer. Advances in Experimental Medicine and Biology, 2020, 1277, 53-62.	1.6	4
88	Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments. Pharmaceutics, 2022, 14, 939.	4.5	4
89	VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clinical and Translational Oncology, 2011, 13, 805-808.	2.4	3
90	Immuno-PET Molecular Imaging of RANKL in Cancer. Cancers, 2021, 13, 2166.	3.7	3

#	Article	IF	Citations
91	Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment: a prospective cohort study. Supportive Care in Cancer, 2022, 30, 21-31.	2.2	3
92	The use of buparlisib as a radiosentisiser: What about toxicity?. European Journal of Cancer, 2019, 119, 194-195.	2.8	2
93	Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey. BMC Women's Health, 2020, 20, 151.	2.0	2
94	Editorial. Gynecologic Oncology, 1996, 62, 322-323.	1.4	1
95	Contribution of ER and NF-Î°B to endocrine resistance in inflammatory breast cancer. Breast Cancer Management, 2014, 3, 53-61.	0.2	1
96	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. Cancer Research, 2022, 82, P1-04-07-P1-04-07.	0.9	1